| P50 | author | Jatin Roper | Q57659291 |
| P2093 | author name string | Wei Chen | |
| | Roderick T Bronson | |
| | Peng-Chieh Chen | |
| | Kenneth E Hung | |
| | Lydia Lee | |
| | Eric S Martin | |
| | Erin M Coffee | |
| | Mark J Sinnamon | |
| | Wei Vivian Wang | |
| | Michael P Richardson | |
| | Larissa Georgeon Richard | |
| P2860 | cites work | Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1 | Q24531380 |
| | Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus | Q24600932 |
| | mTOR: from growth signal integration to cancer, diabetes and ageing | Q24633662 |
| | NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas | Q24646237 |
| | The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations | Q24646816 |
| | NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. | Q27851451 |
| | Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 |
| | The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations | Q27851644 |
| | Cancer statistics, 2010 | Q27860525 |
| | High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 |
| | Defining the role of mTOR in cancer | Q28235431 |
| | Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha | Q28616168 |
| | The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism | Q29547302 |
| | Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 |
| | Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | Q29618117 |
| | Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha | Q30437618 |
| | mTOR and cancer: many loops in one pathway. | Q33348248 |
| | Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells | Q33564297 |
| | Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment | Q33667595 |
| | Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas | Q33896731 |
| | Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs | Q33901504 |
| | The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo | Q33939369 |
| | The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma | Q34001234 |
| | Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells | Q34480703 |
| | The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma | Q34522360 |
| | The role of mTORC1 pathway in intestinal tumorigenesis. | Q43255342 |
| | Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. | Q46047974 |
| | Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging | Q46431103 |
| | Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. | Q46708758 |
| | Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model. | Q53568151 |
| | Systemic treatment of colorectal cancer | Q81253030 |
| | The two TORCs and Akt. | Q34617423 |
| | PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors | Q34769343 |
| | Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma | Q34810176 |
| | Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers | Q34970844 |
| | Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib | Q35177682 |
| | Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy | Q35556966 |
| | The mighty mouse: genetically engineered mouse models in cancer drug development | Q36568461 |
| | Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice | Q36869970 |
| | Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. | Q36983065 |
| | Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance | Q37036297 |
| | Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. | Q37177892 |
| | Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis | Q37242436 |
| | PTEN and the PI3-kinase pathway in cancer | Q37259680 |
| | Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations | Q37382669 |
| | Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. | Q37396608 |
| | Mouse models of colon cancer | Q37407244 |
| | Phosphoinositide signalling in cancer: beyond PI3K and PTEN. | Q37736257 |
| | Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines | Q39513509 |
| | Levels of p27 sensitize to dual PI3K/mTOR inhibition | Q39529578 |
| | The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines. | Q39557570 |
| | mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways | Q39571848 |
| | Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor | Q39591379 |
| | The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. | Q39636381 |
| | Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. | Q39650704 |
| | Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. | Q39653276 |
| | Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease | Q39720433 |
| | Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. | Q39744205 |
| | NVP-BEZ235 as a new therapeutic option for sarcomas. | Q39752874 |
| | Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models | Q39763382 |
| | Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. | Q39827794 |
| | Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. | Q39832054 |
| | The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma | Q39906851 |
| | Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model | Q40182123 |
| | Mutant PIK3CA promotes cell growth and invasion of human cancer cells | Q40410776 |
| | Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. | Q42081736 |
| | Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. | Q42282551 |
| | Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition | Q42452282 |
| | NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. | Q43055104 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| | colorectal carcinoma | Q25493920 |
| P304 | page(s) | e25132 | |
| P577 | publication date | 2011-09-26 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer | |
| P478 | volume | 6 | |